Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.

Sorich MJ, Rowland A, Karapetis CS, Hopkins AM.

J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285-0. doi: 10.1016/j.jtho.2019.04.006. [Epub ahead of print]

PMID:
30999110
2.

Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.

Hopkins AM, Van Dyk M, Rowland A, Sorich MJ.

Pigment Cell Melanoma Res. 2019 Feb 13. doi: 10.1111/pcmr.12773. [Epub ahead of print]

PMID:
30758912
3.

Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology.

Sorich MJ, Mutlib F, van Dyk M, Hopkins AM, Polasek TM, Marshall JC, Rodrigues AD, Rowland A.

J Clin Pharmacol. 2019 Jun;59(6):872-879. doi: 10.1002/jcph.1377. Epub 2019 Jan 11.

PMID:
30633368
4.

Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials.

Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ.

Cancers (Basel). 2018 Oct 15;10(10). pii: E384. doi: 10.3390/cancers10100384.

5.

Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.

Hopkins AM, Rowland A, Sorich MJ.

BMC Med. 2018 Sep 28;16(1):165. doi: 10.1186/s12916-018-1154-z.

6.

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ.

Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19.

PMID:
29574693
7.

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2017 Sep 26;117(7):913-920. doi: 10.1038/bjc.2017.274. Epub 2017 Aug 24. Review.

8.

Population Pharmacokinetic Model of Doxycycline Plasma Concentrations Using Pooled Study Data.

Hopkins AM, Wojciechowski J, Abuhelwa AY, Mudge S, Upton RN, Foster DJ.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02401-16. doi: 10.1128/AAC.02401-16. Print 2017 Mar.

9.

Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis.

Hopkins AM, Wiese MD, O'Doherty CE, Proudman SM.

Clin Rheumatol. 2017 Apr;36(4):791-798. doi: 10.1007/s10067-016-3488-2. Epub 2016 Nov 25.

PMID:
27888342
10.

Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.

Hopkins AM, Moghaddami M, Foster DJ, Proudman SM, Upton RN, Wiese MD.

Drug Metab Dispos. 2017 Jan;45(1):8-16. Epub 2016 Oct 14.

PMID:
27742727
11.

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD.

Med J Aust. 2016 Feb 1;204(2):64-8.

PMID:
26821102
12.

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.

Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Upton RN, Foster DJ.

Br J Clin Pharmacol. 2016 Jan;81(1):113-23. doi: 10.1111/bcp.12760. Epub 2015 Oct 28.

13.

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide.

Hopkins AM, Vitry AI, O'Doherty CE, Proudman SM, Wiese MD.

Int J Rheum Dis. 2017 Nov;20(11):1795-1797. doi: 10.1111/1756-185X.12717. Epub 2015 Jul 14. No abstract available.

PMID:
26176865
14.

Individualization of leflunomide dosing in rheumatoid arthritis patients.

Hopkins AM, O'Doherty CE, Foster DJ, Upton RN, Proudman SM, Wiese MD.

Per Med. 2014 Jun;11(4):449-461. doi: 10.2217/pme.14.23.

PMID:
29783485

Supplemental Content

Loading ...
Support Center